Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H17F2N3O2 |
Molecular Weight | 369.3647 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CCCN(C1)C(=O)C2=CC=C(F)C=C2)C3=NC(=NO3)C4=CC=C(F)C=C4
InChI
InChIKey=VXQCCZHCFBHTTD-HNNXBMFYSA-N
InChI=1S/C20H17F2N3O2/c21-16-7-3-13(4-8-16)18-23-19(27-24-18)15-2-1-11-25(12-15)20(26)14-5-9-17(22)10-6-14/h3-10,15H,1-2,11-12H2/t15-/m0/s1
DescriptionSources: http://www.addextherapeutics.com/fileadmin/user_upload/Media_Exposure/Novel_approach_to_a_drug_discovery.pdfCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23869026
Sources: http://www.addextherapeutics.com/fileadmin/user_upload/Media_Exposure/Novel_approach_to_a_drug_discovery.pdf
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23869026
ADX-47273 is a research pharmaceutical developed by Addex Therapeutics. It is a novel positive allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5). ADX-47273 displays antipsychotic, neuromodulatory, and cognition enhancing activities. In vivo, ADX 47273 increases waking and decreases deep sleep behaviors; it also increases late phase long-term potentiation (LTP) and enhances adaptive learning. In other animal models, ADX-47273 decreases amphetamine- and phencyclidine-induced hyperlocomotion and accumbal dopamine levels.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3227 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24050755 |
157.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19995568
Rats: ADX-47273 (1-100mg/kg) was evaluated in rat models used for detecting antipsychotic-like activity
Route of Administration:
Intraperitoneal
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ADX-47273
Created by
admin on Sat Dec 16 08:09:25 GMT 2023 , Edited by admin on Sat Dec 16 08:09:25 GMT 2023
|
PRIMARY | |||
|
851881-60-2
Created by
admin on Sat Dec 16 08:09:25 GMT 2023 , Edited by admin on Sat Dec 16 08:09:25 GMT 2023
|
PRIMARY | |||
|
DTXSID80234386
Created by
admin on Sat Dec 16 08:09:25 GMT 2023 , Edited by admin on Sat Dec 16 08:09:25 GMT 2023
|
PRIMARY | |||
|
11383075
Created by
admin on Sat Dec 16 08:09:25 GMT 2023 , Edited by admin on Sat Dec 16 08:09:25 GMT 2023
|
PRIMARY | |||
|
4C4P7L0W63
Created by
admin on Sat Dec 16 08:09:25 GMT 2023 , Edited by admin on Sat Dec 16 08:09:25 GMT 2023
|
PRIMARY |
ACTIVE MOIETY